Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) was upgraded by equities research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a note issued to investors on Friday.

Separately, Piper Sandler boosted their target price on Supernus Pharmaceuticals from $33.00 to $38.00 and gave the stock an "overweight" rating in a research note on Wednesday.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN traded down $0.65 during trading hours on Friday, reaching $34.39. The stock had a trading volume of 206,464 shares, compared to its average volume of 417,010. Supernus Pharmaceuticals has a 1 year low of $24.95 and a 1 year high of $36.08. The firm's 50 day moving average is $31.48 and its 200-day moving average is $30.26. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 34.05 and a beta of 1.04.

Insider Activity at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 39,431 shares of the business's stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $31.15, for a total value of $1,228,275.65. Following the completion of the sale, the chief executive officer now directly owns 724,978 shares of the company's stock, valued at approximately $22,583,064.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Jack A. Khattar sold 39,431 shares of the firm's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $31.15, for a total transaction of $1,228,275.65. Following the transaction, the chief executive officer now directly owns 724,978 shares in the company, valued at $22,583,064.70. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Tami Tillotson Martin sold 5,000 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $32.98, for a total transaction of $164,900.00. Following the completion of the sale, the vice president now owns 87,220 shares of the company's stock, valued at approximately $2,876,515.60. The disclosure for this sale can be found here. Insiders sold a total of 66,733 shares of company stock valued at $2,161,863 over the last ninety days. Insiders own 7.99% of the company's stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. IndexIQ Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at about $409,000. Campbell Newman Asset Management Inc. increased its position in Supernus Pharmaceuticals by 2.0% during the 1st quarter. Campbell Newman Asset Management Inc. now owns 22,696 shares of the specialty pharmaceutical company's stock worth $734,000 after purchasing an additional 443 shares during the period. Advisor Resource Council raised its stake in shares of Supernus Pharmaceuticals by 52.8% during the 4th quarter. Advisor Resource Council now owns 78,245 shares of the specialty pharmaceutical company's stock worth $2,281,000 after buying an additional 27,037 shares in the last quarter. Congress Asset Management Co. MA lifted its holdings in shares of Supernus Pharmaceuticals by 17.2% in the 1st quarter. Congress Asset Management Co. MA now owns 464,101 shares of the specialty pharmaceutical company's stock valued at $15,000,000 after buying an additional 67,996 shares during the period. Finally, Retirement Planning Co of New England Inc. boosted its stake in shares of Supernus Pharmaceuticals by 1.3% in the first quarter. Retirement Planning Co of New England Inc. now owns 37,969 shares of the specialty pharmaceutical company's stock valued at $1,227,000 after buying an additional 488 shares in the last quarter. Institutional investors and hedge funds own 99.81% of the company's stock.

Supernus Pharmaceuticals Company Profile

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

See Also

• Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
• Hormel Looks Cheap At These Levels
• Lululemon Set To Soar Into September
• Could Nike Stock be Oversold, but Still Overvalued?
• Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
• Will Royal Caribbean's Broadband Partnership Drive Revenue?

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.